Key facts
- This page summarizes Christopher M. Nelson's Form 4/A filing for QSAM Biosciences, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 Feb 2024, 16:43.
Christopher M. Nelson - 06 Feb 2024 Form 4/A Insider Report for QSAM Biosciences, Inc.
- Reporting relationship
- EVP Corp Dev & General Counsel
- Issuer ticker
- N/A
- Reported as of
- 06 Feb 2024
- Net transaction value
- $0
- SEC form
- 4/A
- Accepted by SEC
- 14 Feb 2024, 16:43:03 UTC
- Original report date
- 13 Feb 2024
- Prior SEC filing
- 23 Jun 2023
- Next SEC filing
- 02 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christopher Nelson
Source evidence
Original filing metadata and source links for verification.
6 source fields
Reporting owner
1 detail
Key filing fact
Christopher M. Nelson filed Form 4/A for QSAM Biosciences, Inc. on 14 Feb 2024.
Change
- Previous filing in this sequence was filed on 23 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4/A disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
QSAM
transaction
Common Stock
Conversion of derivative security
- Transaction value
- $26,049
- Shares
- +8,683
- Change %
- +5%
- Price
- $3.00*
- Shares after
- 182,000
- Date
- 06 Feb 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
QSAM
transaction
Derivative
Series B Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- $26,049
- Shares
- Change %
- Price
- Shares after
- 0
- Date
- 06 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,683
- Exercise price
- $3.00
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Correction to footnote: On February 13, 2024, the reporting person filed a Form 4 which inadvertently reported in footnote 1 that the date of the Exchange Agreements between the Issuer and all the Series B stockholders was 11/18/2023. It is hereby corrected that the Exchange Agreements were entered into between the dates of 10/16/2023 and 10/23/2023.